RU2306309C2 - Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний - Google Patents

Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний Download PDF

Info

Publication number
RU2306309C2
RU2306309C2 RU2004129584/04A RU2004129584A RU2306309C2 RU 2306309 C2 RU2306309 C2 RU 2306309C2 RU 2004129584/04 A RU2004129584/04 A RU 2004129584/04A RU 2004129584 A RU2004129584 A RU 2004129584A RU 2306309 C2 RU2306309 C2 RU 2306309C2
Authority
RU
Russia
Prior art keywords
formula
alkyl
nmr
tlc
cdcl
Prior art date
Application number
RU2004129584/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004129584A (ru
Inventor
Коусуке ТАНИ (JP)
Коусуке ТАНИ
Каору КОБАЯСИ (JP)
Каору КОБАЯСИ
Тору МАРУЯМА (JP)
Тору МАРУЯМА
Тохру КАМБЕ (JP)
Тохру КАМБЕ
Микио ОГАВА (JP)
Микио ОГАВА
Цутому СИРОЯ (JP)
Цутому СИРОЯ
Original Assignee
Оно Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оно Фармасьютикал Ко., Лтд. filed Critical Оно Фармасьютикал Ко., Лтд.
Publication of RU2004129584A publication Critical patent/RU2004129584A/ru
Application granted granted Critical
Publication of RU2306309C2 publication Critical patent/RU2306309C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
RU2004129584/04A 2002-03-05 2003-03-04 Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний RU2306309C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002058487 2002-03-05
JP2002-58487 2002-03-05
JP2002216567 2002-07-25
JP2002-216567 2002-07-25
JP2003-13447 2003-01-22
JP2003013447 2003-01-22

Publications (2)

Publication Number Publication Date
RU2004129584A RU2004129584A (ru) 2005-05-27
RU2306309C2 true RU2306309C2 (ru) 2007-09-20

Family

ID=27792041

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004129584/04A RU2306309C2 (ru) 2002-03-05 2003-03-04 Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний

Country Status (16)

Country Link
US (3) US7402605B2 (pl)
EP (1) EP1481976B1 (pl)
JP (2) JP4547912B2 (pl)
KR (1) KR100704215B1 (pl)
CN (1) CN1653046A (pl)
AU (1) AU2003211574A1 (pl)
BR (1) BR0308166A (pl)
CA (1) CA2477715A1 (pl)
IL (1) IL163866A0 (pl)
MX (1) MXPA04008596A (pl)
NO (1) NO20043702L (pl)
NZ (1) NZ535024A (pl)
PL (1) PL372084A1 (pl)
RU (1) RU2306309C2 (pl)
TW (1) TW200305425A (pl)
WO (1) WO2003074483A1 (pl)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481342C2 (ru) * 2007-10-23 2013-05-10 Аллерган, Инк. Терапевтические замещенные лактамы
RU2509768C2 (ru) * 2008-09-10 2014-03-20 Асахи Гласс Компани, Лимитед Новое производное простагландина i2
RU2531350C2 (ru) * 2009-06-10 2014-10-20 Оно Фармасьютикал Ко., Лтд. Соединение, обладающее сокращающей детрузор активностью и релаксирующей уретральный сфинктер активностью
RU2543379C2 (ru) * 2008-04-24 2015-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
RU2564414C2 (ru) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. Новый агонист ер4
RU2658823C2 (ru) * 2012-08-31 2018-06-25 Оно Фармасьютикал Ко., Лтд. Аминовая соль и ее кристаллы

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
WO2004089411A1 (ja) * 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
CN101675928A (zh) * 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
US7833995B2 (en) 2003-12-05 2010-11-16 Ono Pharmaceutical Co., Ltd. Blood flow promoters for cauda equina tissues
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
ATE465986T1 (de) 2005-01-14 2010-05-15 Allergan Inc Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
CA2599425C (en) * 2005-03-10 2013-04-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2006253356B2 (en) 2005-06-03 2011-12-01 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US7323591B2 (en) 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US7507833B2 (en) 2006-08-10 2009-03-24 Allergan, Inc. Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives
CN101522669B (zh) 2006-08-11 2013-01-16 阿勒根公司 治疗用内酰胺
US7795287B2 (en) 2006-09-01 2010-09-14 Allergan, Inc. Therapeutic substituted hydantoins and related compounds
WO2008058766A1 (en) 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
KR20080055355A (ko) * 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
EP2120962A1 (en) * 2006-12-18 2009-11-25 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008094912A2 (en) * 2007-01-31 2008-08-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ES2404169T3 (es) * 2007-02-15 2013-05-24 Allergan, Inc. Gamma-láctamicos para el tratamiento de glaucoma o la presión intraocular elevada
AU2008215431C1 (en) 2007-02-16 2013-10-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
HUE042839T2 (hu) 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US8592413B2 (en) 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
HRP20160104T1 (hr) 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
WO2014015247A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
JPWO2014157672A1 (ja) 2013-03-28 2017-02-16 宇部興産株式会社 置換ビアリール化合物
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
NZ733575A (en) 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound
CA3015494C (en) * 2016-03-30 2021-10-26 Ayuvis Research, Inc. Novel compositions and therapeutic methods
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001233792A (ja) * 2000-01-31 2001-08-28 Pfizer Prod Inc 急性及び慢性腎不全の処置のためのプロスタグランジン（ｐｇｅ２）受容体４（ｅｐ４）選択的アゴニストの使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS511461A (en) 1974-06-24 1976-01-08 Tanabe Seiyaku Co 88 azapurosutansanjudotainoseiho
GB1529852A (en) 1975-03-21 1978-10-25 Labaz 8-azaprostaglandins and process for the preparation thereof
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2556326A1 (de) 1975-12-13 1977-06-23 Hoechst Ag Neue pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
EP0471201A1 (de) 1990-07-21 1992-02-19 Hoechst Aktiengesellschaft Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
US5280034A (en) * 1991-08-23 1994-01-18 E. R. Squibb & Sons, Inc. Bis-heterocyclic prostaglandin analogs
IT1254373B (it) 1992-05-29 1995-09-14 Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
GEP20043203B (en) * 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
OA12533A (en) 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
CN100371322C (zh) * 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
EP2255829A3 (en) * 2001-07-23 2012-03-28 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
WO2003047417A2 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
EP1461026A2 (en) * 2001-12-03 2004-09-29 Merck & Co., Inc. Method for treating ocular hypertension
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001233792A (ja) * 2000-01-31 2001-08-28 Pfizer Prod Inc 急性及び慢性腎不全の処置のためのプロスタグランジン（ｐｇｅ２）受容体４（ｅｐ４）選択的アゴニストの使用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481342C2 (ru) * 2007-10-23 2013-05-10 Аллерган, Инк. Терапевтические замещенные лактамы
RU2481342C9 (ru) * 2007-10-23 2013-07-20 Аллерган, Инк. Терапевтические замещенные лактамы
RU2543379C2 (ru) * 2008-04-24 2015-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
RU2509768C2 (ru) * 2008-09-10 2014-03-20 Асахи Гласс Компани, Лимитед Новое производное простагландина i2
RU2531350C2 (ru) * 2009-06-10 2014-10-20 Оно Фармасьютикал Ко., Лтд. Соединение, обладающее сокращающей детрузор активностью и релаксирующей уретральный сфинктер активностью
RU2564414C2 (ru) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. Новый агонист ер4
RU2658823C2 (ru) * 2012-08-31 2018-06-25 Оно Фармасьютикал Ко., Лтд. Аминовая соль и ее кристаллы

Also Published As

Publication number Publication date
US20100113388A1 (en) 2010-05-06
JP4547912B2 (ja) 2010-09-22
US20090042885A1 (en) 2009-02-12
KR100704215B1 (ko) 2007-04-10
US8026273B2 (en) 2011-09-27
PL372084A1 (pl) 2005-07-11
CA2477715A1 (en) 2003-09-12
BR0308166A (pt) 2005-01-18
US7683094B2 (en) 2010-03-23
MXPA04008596A (es) 2004-12-06
NZ535024A (en) 2006-10-27
JP2010077142A (ja) 2010-04-08
EP1481976B1 (en) 2012-11-07
JPWO2003074483A1 (ja) 2005-06-30
KR20040095264A (ko) 2004-11-12
NO20043702L (no) 2004-12-03
US20050124577A1 (en) 2005-06-09
IL163866A0 (en) 2005-12-18
WO2003074483A1 (en) 2003-09-12
US7402605B2 (en) 2008-07-22
RU2004129584A (ru) 2005-05-27
EP1481976A4 (en) 2006-01-18
CN1653046A (zh) 2005-08-10
TW200305425A (en) 2003-11-01
AU2003211574A1 (en) 2003-09-16
EP1481976A1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
RU2306309C2 (ru) Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
JP5387699B2 (ja) Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
JP4582456B2 (ja) ８−アザプロスタグランジン誘導体およびその医薬用途
JP4893999B2 (ja) 吸入用医薬組成物
CN1893977B (zh) 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090305